308 related articles for article (PubMed ID: 29626277)
1. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
[TBL] [Abstract][Full Text] [Related]
2. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
4. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
6. Applying simple linear combination, multiple logistic and factor analysis methods for candidate fecal bacteria as novel biomarkers for early detection of adenomatous polyps and colon cancer.
Rezasoltani S; Sharafkhah M; Asadzadeh Aghdaei H; Nazemalhosseini Mojarad E; Dabiri H; Akhavan Sepahi A; Modarressi MH; Feizabadi MM; Zali MR
J Microbiol Methods; 2018 Dec; 155():82-88. PubMed ID: 30439465
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
[TBL] [Abstract][Full Text] [Related]
8. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
Trials; 2015 Jul; 16():296. PubMed ID: 26156248
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
10. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.
Sithambaram S; Hilmi I; Goh KL
PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
[TBL] [Abstract][Full Text] [Related]
12. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
Tonus C; Neupert G; Sellinger M
World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
[TBL] [Abstract][Full Text] [Related]
14. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
15. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
16. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
17. LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.
Rodia MT; Solmi R; Pasini F; Nardi E; Mattei G; Ugolini G; Ricciardiello L; Strippoli P; Miglio R; Lauriola M
Clin Colorectal Cancer; 2018 Jun; 17(2):e217-e228. PubMed ID: 29352642
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
19. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
[TBL] [Abstract][Full Text] [Related]
20. The fecal occult blood test as a tool for improved outpatient qualification for colonoscopy. A single-center experience and 10-year follow-up survey.
Banaszkiewicz Z; Budzyński J; Tojek K; Jarmocik P; Frasz J; Mrozowski M; Świtoński M; Jawień A
Adv Med Sci; 2017 Mar; 62(1):171-176. PubMed ID: 28282604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]